TITLE

Vaginal mucosal vaccine for recurrent urinary tract infections

AUTHOR(S)
Gautam, Gagan; Khera, Rakesh
PUB. DATE
July 2007
SOURCE
Indian Journal of Urology;Jul-Sep2007, Vol. 23 Issue 3, p335
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The authors conducted a randomized double-blind placebo-controlled study to assess the clinical efficacy of vaginal placebo only (n = 25), primary immunization without boosters (n = 24) or primary immunization plus boosters (n = 26) using vaginal suppositories containing placebo or vaccine. Vaccine suppositories contained 10 strains of heat-killed uropathogenic bacteria (a total of 109 organisms from six strains of E. coli and one each of Proteus, Morganella, Klebsiella and E. fecalis in a polyethylene glycol base) and placebo suppositories had no vaccine organisms. Primary immunization consisted of three suppositories given at weekly intervals while boosters were given in three doses at monthly intervals after completion of the primary doses. All women were monitored for six months to record the number of infections and adverse events.
ACCESSION #
26156342

 

Related Articles

  • High-tech vaccine may hold key to UTI prevention. Bauman, Norman // Urology Times;Jun97, Vol. 25 Issue 6, p1 

    Reports on the development of a vaccine against Escherichia coli-induced urinary tract infections. Schedule of human trials; Results of clinical trials in mice; Features and capabilities of recombinant pili vaccine; Tendency of vaccines to target bladder-specific adhesins.

  • Vaginal Mucosal Immunization for Recurrent Urinary Tract Infection: Extended Phase II Clinical Trial. Uehling, David T.; Hopkins, Walter J.; Beierle, Lori M.; Kryger, John V.; Heisey, Dennis M. // Journal of Infectious Diseases;3/2/2001 Supplement 1, Vol. 183, pS81 

    Presents information on a study which examined vaginal mucosal immunization in women with urinary tract infection. Materials and methods; Results and discussion.

  • Is there a correlation between the size of the BCG scar and renal scar of urinary tract infections in children? Kavukçu, Salih; Alaygut, Demet; Kasap, Belde; Soylu, Alper; Çapakaya, Gamze; Türkmen, Mehmet // Journal of Clinical & Experimental Investigations / Klinik ve De;Mar2013, Vol. 4 Issue 1, p8 

    Objective: Pyelonephritis cause cellular death, and development of scars in kidneys. The aim of this study is to demonstrate a correlation (if any) between renal scar, and size of the scar induced by BCG vaccine in children who had experienced urinary tract infections. In case of detection of...

  • Adolescent female presents with painful rash on neck, ear. Brien, James H. // Infectious Diseases in Children;Jan2013, Vol. 26 Issue 1, p16 

    The article presents a case of an adolescent female who complained of a painful rash on the right side of her neck and ear which developed after she received an injection for urinary tract infection.

  • Vaginal vaccine promising for recurrent UTIs. Bankhead, Charles // Urology Times;Jul2000, Vol. 28 Issue 7, p16 

    Presents results of a study conducted by Walter Hopkins from the University of Wisconsin in Madison's department of surgery on immunization with vaccine embedded vaginal suppositories for women with recurrent urinary tract infections (UTI). Resistance to re-infection after vaccine...

  • Vaccination Utilizing the FimCH Complex As a Strategy to Prevent Escherichia coli Urinary Tract Infections. Langermann, Solomon; Ballou Jr., W. Ripley // Journal of Infectious Diseases;3/2/2001 Supplement 1, Vol. 183, pS84 

    Focuses on the efficacy of FimH of type 1 pili vaccine as strategy to prevent Escherichia coli urinary tract infections (UTI). Role of pilus proteins in UTI; Commentary.

  • FimH adhesin molecule targeted in new UTI vaccines. Taggart, Martha // Urology Times;Jul2001, Vol. 29 Issue 7, p17 

    Reports on vaccines being developed against uropathogenic Escherichia coli, the causative agent of majority of urinary tract infections as of July 2001. MedImmune's development of a vaccine against the FimH adhesin molecule which mediates Escherichia coli's binding to the bladder mucosa.

  • Treatment-resistant UTI vaccine moves closer to reality. Allen, Penny // Urology Times;Dec2009, Vol. 37 Issue 13, p18 

    The article reports on the looming arrival of the urinary tract infection (UTI) vaccine in the U.S. It notes that the vaccine will alleviate the economic burden brought by UTI and put an end to the challenge of recurrent UTIs. It mentions that the potential new vaccine is a live attenuated...

  • Miscellaneous.  // Current Medical Literature: Urology;2007, Vol. 13 Issue 3, p83 

    Two abstracts are presented including "Burch colposuspension versus fascial sling to reduce urinary stress incontinence," by M. E. Albo et al, and "Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial," by W. J. Hopkins et al.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics